Regeneron, Sanofi Cite Progress in Pursuing Eosinophilic Esophagitis Indication for Dupixent

Regeneron and Sanofi today reported progress toward adding new food allergy indications for their marketed drug Dupixent ® (dupilumab) with announcements of successful Phase II results in adults with active moderate-to-severe eosinophilic esophagitis, and the launch of a Phase II study with Aimmune Therapeutics assessing the treatment in peanut-allergic patients.At the World Congress of Gastroenterology (WCOG), held in partnership with The American College of Gastroenterology Annual Scientif